Management of Severe Vitamin D Deficiency (25‑OH‑D ≤ 8 ng/mL)

Severity Classification

A serum 25‑hydroxyvitamin D level ≤ 8 ng/mL is classified as severe deficiency ( < 20 ng/mL) and warrants aggressive repletion to achieve a target ≥ 30 ng/mL. 1

Loading dose: 50,000 IU vitamin D₃ (cholecalciferol) administered once weekly for 8 weeks (total 400,000 IU) is the standard evidence‑based regimen for adults with severe deficiency; it is expected to raise serum 25‑OH‑D by ~40–60 ng/mL, reaching the 30–50 ng/mL target range. 1
Formulation preference: Vitamin D₃ is strongly preferred over vitamin D₂ because it sustains serum concentrations longer and produces a greater increase in 25‑OH‑D levels. 1

Daily dose alternative: 5,000–6,000 IU vitamin D₃ taken each day for 8–12 weeks provides an equally effective repletion strategy and avoids large intermittent spikes. 2
Indications for daily dosing: Consider daily dosing in patients with malabsorption, obesity (BMI > 30), or those receiving enzyme‑inducing medications (e.g., anticonvulsants, glucocorticoids). 1

Serum check: Re‑measure 25‑OH‑D 8–12 weeks after initiating therapy to confirm an adequate response and guide further management. 1
Inadequate response (< 30 ng/mL despite adherence):

Standard maintenance: After achieving ≥ 30 ng/mL, continue with 2,000 IU vitamin D₃ daily for long‑term maintenance. 1
Adjusted maintenance for special groups: In obese individuals or those with malabsorption, a higher maintenance dose of 3,000–6,000 IU daily may be required to sustain target levels. 1

Weekly high‑dose safety: The 50,000 IU weekly regimen for 8 weeks is safe in adults without granulomatous disease or primary hyperparathyroidism and does not cause hypercalcemia or toxicity. 1
Avoid annual bolus dosing: Large once‑yearly doses (e.g., 500,000 IU) are associated with increased falls and fractures in older adults and should be avoided. 2
Calcium monitoring: Check serum calcium in patients with sarcoidosis, tuberculosis, lymphoma, or primary hyperparathyroidism, as these conditions predispose to hypercalcemia with supplementation. 1
Toxicity threshold: Vitamin D toxicity is rare and occurs only with chronic daily intakes > 50,000 IU that raise 25‑OH‑D > 150 ng/mL; the recommended regimens remain well below this threshold. 2

Low‑dose regimens (800–1,000 IU daily) are insufficient for correcting severe deficiency and should not be used. 1
Assume variable individual response: Follow‑up testing at 8–12 weeks is essential because absorption and metabolism differ among patients. 3
Do not use calcitriol or other activated vitamin D analogs for nutritional deficiency, as they do not replenish 25‑OH‑D stores and carry a higher hypercalcemia risk. 3
Ensure adequate calcium intake: Recommend total dietary and supplemental calcium of 1,000–1,200 mg/day to optimize bone health and vitamin D efficacy. 3

Obesity (BMI > 30): Require 2–3 × the standard dose (6,000–10,000 IU daily or 50,000 IU twice weekly for 8 weeks) because vitamin D is sequestered in adipose tissue. 1
Malabsorption syndromes (celiac disease, Crohn’s disease, cystic fibrosis, chronic pancreatitis): May need 6,000–10,000 IU daily or 50,000 IU twice weekly to achieve target levels. 1
Enzyme‑inducing medications (phenytoin, carbamazepine, rifampin, glucocorticoids): Higher maintenance doses of 4,000–6,000 IU daily are recommended to offset increased vitamin D metabolism. 1